๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changzhou
Clinical trial register · China

Clinical Trials in Changzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC20 Eli Lilly and Company12 AstraZeneca12 The First People's Hospital of Changzhou5 The First Affiliated Hospital with Nanjing Medical University5
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Changzhou

120 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT07382375Aortic Aneurysm and Dissection
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy
NCT07769671Diabetic Nephropathy Type 2
The First People's Hospital of Changzhou
Phase 1/2
49
Changzhou
2026-09-01
Recruiting
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
NCT07775404Obesity, Overweight
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naรฏve Mantle Cell Lymphoma (MCL)
NCT07719556Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Changzhou, Nanjing
2026-07-15
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
NCT07673640Non-Segmental Vitiligo (NSV)
ShanShan Li
Observational
300
Shenzhen, Huai'an, Suzhou, Xuzhou, Dongying, Shanghai, Changzhou, Jiaozuo
2026-07-02
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Not yet open
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
NCT07550842Small Cell Carcinoma of Lung
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Not yet open
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
NCT07622550Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chongqing, Guangzhou, Huai'an, Ningbo, Shijiazhuang, Zhuzhou
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changzhou, Chongqing, Guangzhou, Hangzhou, Huai'an, Ningbo, Zhuzhou
2026-05-22
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Changzhou, Chongqing, Guangzhou, Nanjing, Wuhan
2026-04-21
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Not yet open
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Recruiting
Safety and Efficacy of CAG and PCI Via Distal Transradial Access in Patients With Small Vessels
NCT07410364Coronary Artery Disease
Cai gaojun, MD
Not applicable
594
Changzhou
2026-02-24
Not yet open
Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis
NCT07319338Chronic Atrophic Gastritis, Depressive Symptoms, Depression, Gastrointestinal Diseases
China Academy of Chinese Medical Sciences
Observational
520
Beijing, Hengshui, Changzhou
2026-02-01
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Recruiting
Compilation and Preliminary Application of the Active Health Behavior Scale in Patients With Type 2 Diabetes
NCT07531459Type 2 Diabetes
Yun Ye
Observational
600
Changzhou
2025-12-24
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
By invitation
Non-Invasive Brain-Computer Interface Combined With Transcranial Electrical Stimulation for Peripheral Facial PalsyStimulation in the Treatment of Peripheral Facial Palsy
NCT07327710Peripheral Facial Palsy, Pulsed Radiofrequency, Brain-Computer Interface, Transcranial Direct Current Stimulation
Nanjing Medical University
Not applicable
30
Changzhou
2025-11-30
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
NCT07187687Intracerebral Hemorrhage
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
NCT06862206Chronic Obstructive Pulmonary Disease
AstraZeneca
Observational
1,000
Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou
2025-07-11
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Active, closed
A Study for the Evaluation of Efficacy and Safety of Proliaยฎ in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153Glucocorticoid-induced Osteoporosis
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
Not yet open
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647HBV, Chronic Hepatitis b
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Not yet open
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
Changzhou No.2 People's Hospital
Phase 1
18
Changzhou
2025-05
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, รœrรผmqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
NCT06801665Colorectal Cancer Liver Metastasis
Hua Jiang
Phase 2
30
Changzhou
2025-04-17
Recruiting
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
NCT07348302Rhinitis, Rhinoconjunctivitis
Inmunotek S.L.
Phase 3
736
Beijing, Guangzhou, Zhongshan, Xiangya, Changzhou, Qingdao, Shanghai, Tongji
2025-04-02
Not yet open
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
NCT06838520Prostate Cancer (Adenocarcinoma)
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Changzhou, Nanjing, Suzhou, Yangzhou
2025-04-01
Active, closed
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486Obesity and Overweight
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Harbin, Hefei
2025-03-27
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology
NCT07050537Fertility Issues, Blastocyst IVF, Embryo Culture
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xiโ€™an
2025-03-01
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Active, closed
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
NCT06829329Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
Sanofi
Phase 2
260
Changzhou, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanchang, Shanghai
2024-12-10
Active, closed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
NCT06834932Dyslipidaemia
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Recruiting
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
NCT06867991Anti-N-Methyl-D-Aspartate Receptor Encephalitis
The First People's Hospital of Changzhou
Phase 3
200
Zhengzhou, Changzhou
2024-11-08
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Recruiting
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
NCT06090994Colorectal Cancer
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Recruiting
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
NCT06337474Thrombocytopenia Alloimmune
Changzhou No.2 People's Hospital
Phase EARLY_PHASE1
9
Changzhou
2024-08-30
Active, closed
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT06452537Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
NCT06413953Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Active, closed
Exoskeleton Training on Balance Control and Turning in Ambulation in Individuals With Incomplete Spinal Cord Injury
NCT06971510Spinal Cord Injuries
Hong Kong Metropolitan University
Not applicable
32
Changzhou, Nanjing, Hong Kong
2024-06-01
Recruiting
FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
NCT06405113Gastric Cancer
Changzhou No.2 People's Hospital
Phase 2
198
Changzhou
2024-06-01
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994Mantle Cell Lymphoma
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
NCT06456515Colorectal Cancer Metastatic
The First People's Hospital of Changzhou
Not applicable
30
Changzhou
2024-05-01
Recruiting
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
NCT06497738Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Observational
112
Changzhou, Nanjing, Nantong, Taizhou, Yancheng
2024-05-01
By invitation
Clinical Trial of Safety and Efficacy of Intracranial Laser Balloon Dilation Catheter in Patients With Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multi-center, Randomized Comparison
NCT06950242Prospective, Multicenter, Randomized, Controlled, and Superior Efficiency
The First People's Hospital of Changzhou
Not applicable
128
Changzhou
2024-04-11
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
579
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Not yet open
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction๏ผŒa Phase II Clinical Study
NCT06241469Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Wu Jun
Phase 2
40
Changzhou
2024-02-03
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Active, closed
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
NCT07065786Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Observational
550
Changzhou
2024-01-01
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Recruiting
Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters
NCT06964867Vitreous Floaters, Anxiety
Changzhou No.2 People's Hospital
Not applicable
300
Changzhou
2023-12-01
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029Osteoporotic Fractures
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925ST Elevation Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naรฏve Participants With Acute Myeloid Leukemia
NCT05736965AML, Adult
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Chโ€™ang-chโ€™un, Haโ€™erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Recruiting
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
NCT05661786Chronic Hepatitis b
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Not yet open
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
NCT05181501Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Rows per page Showing 1–100 of 120
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/changzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 120 of those studies with a site in Changzhou.

How many clinical trials are recruiting in Changzhou?

64 of the 120 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 12 have not yet opened recruitment, 42 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changzhou), 120 studies
PhaseStudiesRecruitingShare
Phase 3532644.2%
Phase 2221418.3%
Observational161113.3%
Not applicable12710%
Phase 2/3615%
Phase 1413.3%
Phase 1/2312.5%
Phase 4322.5%
Phase EARLY_PHASE1110.8%

Most active sponsors

Lead sponsors with the most studies (Changzhou)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC208
AstraZeneca126
Eli Lilly and Company127
The First Affiliated Hospital with Nanjing Medical University54
The First People's Hospital of Changzhou52
Changzhou No.2 People's Hospital43
Nanjing Medical University31
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School33
Ausper Biopharma Co., Ltd.21
Daiichi Sankyo22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.